Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.

Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores

Indexado en
  • Índice Copérnico
  • Google Académico
  • Abrir puerta J
  • Revista GenámicaBuscar
  • Infraestructura Nacional del Conocimiento de China (CNKI)
  • Biblioteca de revistas electrónicas
  • Búsqueda de referencia
  • Universidad Hamdard
  • EBSCO AZ
  • OCLC-WorldCat
  • Biblioteca Virtual de Biología (vifabio)
  • publones
  • Fundación de Ginebra para la educación y la investigación médicas
  • Pub Europeo
  • ICMJE
Comparte esta página

Abstracto

Impact of Glasgow Prognostic Score on Advanced Cancer Patients in Palliative Care Settings: A Short Narrative Review

Tomofumi Miura and Yoshihisa Matsumoto

Advanced cancer patients gradually experience deterioration of their physical condition and symptoms. Prognostic information is quite important for patients, their caregivers and medical staff. The Glasgow Prognostic Score (GPS)/modified GPS (mGPS) is one of the objective prognostic indicators. This study aimed to review the prevalence of GPS/mGPS and its impact on the prognostic value, physical function, quality of life and symptoms, and cancer cachexia among cancer patients who had received supportive care without plan of any anti-tumor therapy. Six studies were identified. The increase in GPS/mGPS score was correlated with poor prognosis, poor performance status and weight loss in patients without anti-tumor therapy. However, no evidence about the correlation between GPS/mGPS and activities of daily living, quality of life and symptoms existed. More detailed classification of GPS/mGPS will be needed to adequately reflect the general conditions of advanced cancer patients who have received supportive care without plan of any anti-tumor therapy.